Historical Valuation
Cardiff Oncology Inc (CRDF) is now in the Fair zone, suggesting that its current forward PS ratio of 518.46 is considered Fairly compared with the five-year average of -4.27. The fair price of Cardiff Oncology Inc (CRDF) is between 1.13 to 5.39 according to relative valuation methord.
Relative Value
Fair Zone
1.13-5.39
Current Price：3.17
Fair
P/E
EV/EBITDA
EV/EBIT
P/S
P/OCF
P/FCF
1Y
3Y
5Y
Trailing
Forward
Cardiff Oncology Inc (CRDF) has a current Price-to-Book (P/B) ratio of 3.66. Compared to its 3-year average P/B ratio of 2.09 , the current P/B ratio is approximately 75.14% higher. Relative to its 5-year average P/B ratio of 1.86, the current P/B ratio is about 96.38% higher. Cardiff Oncology Inc (CRDF) has a Forward Free Cash Flow (FCF) yield of approximately -23.59%. Compared to its 3-year average FCF yield of -32.81%, the current FCF yield is approximately -28.10% lower. Relative to its 5-year average FCF yield of -28.23% , the current FCF yield is about -16.44% lower.
P/B
Median3y
2.09
Median5y
1.86
FCF Yield
Median3y
-32.81
Median5y
-28.23
Competitors Valuation Multiple
AI Analysis for CRDF
The average P/S ratio for CRDF competitors is 88.01, providing a benchmark for relative valuation. Cardiff Oncology Inc Corp (CRDF.O) exhibits a P/S ratio of 518.46, which is 489.11% above the industry average. Given its robust revenue growth of -27.27%, this premium appears unsustainable.
Performance Decomposition
AI Analysis for CRDF
1Y
3Y
5Y
Market capitalization of CRDF increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.
The secondary factor is the Unknown, contributed 0.00%to the performance.
Overall, the performance of CRDF in the past 1 year is driven by Unknown.
People Also Watch
Frequently Asked Questions
Is CRDF currently overvalued or undervalued?
Cardiff Oncology Inc (CRDF) is now in the Fair zone, suggesting that its current forward PS ratio of 518.46 is considered Fairly compared with the five-year average of -4.27. The fair price of Cardiff Oncology Inc (CRDF) is between 1.13 to 5.39 according to relative valuation methord.
What is Cardiff Oncology Inc (CRDF) fair value?
CRDF's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of Cardiff Oncology Inc (CRDF) is between 1.13 to 5.39 according to relative valuation methord.
How does CRDF's valuation metrics compare to the industry average?
The average P/S ratio for CRDF's competitors is 88.01, providing a benchmark for relative valuation. Cardiff Oncology Inc Corp (CRDF) exhibits a P/S ratio of 518.46, which is 489.11% above the industry average. Given its robust revenue growth of -27.27%, this premium appears unsustainable.
What is the current P/B ratio for Cardiff Oncology Inc (CRDF) as of Jan 09 2026?
As of Jan 09 2026, Cardiff Oncology Inc (CRDF) has a P/B ratio of 3.66. This indicates that the market values CRDF at 3.66 times its book value.
What is the current FCF Yield for Cardiff Oncology Inc (CRDF) as of Jan 09 2026?
As of Jan 09 2026, Cardiff Oncology Inc (CRDF) has a FCF Yield of -23.59%. This means that for every dollar of Cardiff Oncology Inc’s market capitalization, the company generates -23.59 cents in free cash flow.
What is the current Forward P/E ratio for Cardiff Oncology Inc (CRDF) as of Jan 09 2026?
As of Jan 09 2026, Cardiff Oncology Inc (CRDF) has a Forward P/E ratio of -3.59. This means the market is willing to pay $-3.59 for every dollar of Cardiff Oncology Inc’s expected earnings over the next 12 months.
What is the current Forward P/S ratio for Cardiff Oncology Inc (CRDF) as of Jan 09 2026?
As of Jan 09 2026, Cardiff Oncology Inc (CRDF) has a Forward P/S ratio of 518.46. This means the market is valuing CRDF at $518.46 for every dollar of expected revenue over the next 12 months.